Physician profile
Fernando S Mora Mclaughlin
NPI 1942381405
$28,190.14
in general payments reported to CMS, 2019-2025
46 companies · $4,762 in 2025
The $4,762 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,685 · 2020: $2,775 · 2021: $4,926 · 2022: $3,328 · 2023: $3,023 · 2024: $3,691 · 2025: $4,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,475.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,121.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $3,722.61 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Abbvie INC. | $2,239.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,660.16 | 2019-2024 | Cyltezo |
| Gilead Sciences, INC. | $1,602.04 | 2019-2025 | Biktarvy |
| Astrazeneca Pharmaceuticals LP | $1,522.02 | 2019-2025 | Farxiga, Lokelma |
| Janssen Biotech, INC. | $1,432.95 | 2019-2023 | Symtuza |
| Intra-Sana Laboratories | $1,260.36 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Janssen Products, LP | $1,183.46 | 2019-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $908.14 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $890.54 | 2019-2024 | Eliquis, Camzyos |
| Xeris Pharmaceuticals, INC. | $779.53 | 2024-2025 | Recorlev |
| Amgen INC. | $724.79 | 2019-2025 | Repatha, Repatha, Otezla |
| Dexcom, INC. | $690.05 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $678.29 | 2019-2025 | Relistor |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Mora Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.